Changes in ownership in Orexo AB - new number of shares and

Changes in ownership in Orexo AB - new number of shares and votes

 

Uppsala, July 29, 2011 - Following the successful completion of the
rights issue providing gross proceeds of approximately MSEK 245 in June
2011, Orexo is pleased to announce the resulting significant changes in
ownership as well as number of shares.

As per July 29, 2011 the total number of shares and votes in Orexo
amounts to 29,850,940, which corresponds to an increase by 6,438,188
shares.

A key objective of the financing, which was conducted with pre-emptive
rights for existing shareholders, was to enable new international
institutional investors to join as owners of Orexo. As evidenced by the
top-10 shareholder list below, the company secured major subscriptions
from both Denmark's largest pension fund Arbejdsmarkedets
Tillaegspension (ATP) as well as the specialist life science investor
Abingworth. Furthermore, Novo A/S increased its holding significantly
and is now the largest shareholder of Orexo.

Shareholder                             Shares      % of total
Novo A/S                                7 182 658   24,1%
HealthCap                               5 632 971   18,9%
Arbejdsmarkedets Tillaegspension (ATP)  1 578 947   5,3%
Third Swedish National Pension Fund     1 176 798   3,9%
Rasjö, Staffan                          1 087 120   3,6%
Fourth Swedish National Pension Fund    1 032 898   3,5%
Försäkringsaktiebolaget Avanza pension  811 314     2,7%
Abingworth                              789 474     2,6%
Lundqvist, Thomas                       495 250     1,7%
Others                                  10 063 510  33,7%
Total number of shares                  29 850 940  100,0%

For further information, please contact:

Anders Lundström, President and CEO of Orexo

Tel: +46 (0)70-667 22 66

E-mail: anders.lundström@orexo.com (anders.lundström@orexo.com)

About Orexo

Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. The company has four commercialized products,
several projects developed in partnership as well as three proprietary
development programs. Orexo's registered products are Abstral® for the
treatment of break through cancer pain, sold by Kyowa Hakko
Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill
Edluar™, sold by Meda in the USA, as well as two products for the
diagnosis of Helicobacter pylori which are being marketed by the
subsidiary Kibion. More information can be found at www.orexo.com.

Note: Orexo discloses the information provided in this press release
pursuant to the Financial Instruments Trading Act. The information was
provided for public release on July 29, 2011 at 2.00 p.m. CET.
Changes in ownership in Orexo AB - new number of shares and votes

Attachments
